Characterization of a fit-for-purpose commercial rapid mycoplasma PCR test solution for routine quality control
Cell & Gene Therapy Insights 2022; 8(1), 1;
10.18609/cgti.2022.023
Published: 3 February 2022
FastFacts
Watch the video or read the poster to learn about
- Why mycoplasma contamination poses a significant safety and economic risk to biopharmaceutical manufacturers
- Nucleic acid amplification technique (NAT)-based assays as rapid, sensitive, and reproducible alternatives to direct agar culture
- How fast and accurate mycoplasma detection can support the evolving needs of cell and gene therapy developers through commercial manufacturing